Cipher Pharmaceuticals announces fourth-quarter and fiscal season 2009 results Cipher Pharmaceuticals Inc. today announced its monetary and operational results for the fourth quarter and fiscal 12 months ended December 31, 2009. Fiscal 2009 Overview – Total revenue a lot more than doubled to $3 stamina boost .2 million, driven by growth of Lipofen prescriptions. – Strong balance sheet at year end with cash of $9.0 million no debt, weighed against cash of $9.9 million at December 31, 2008. – Commenced CIP-ISOTRETINOIN Phase III security trial in Q3; with 176 patients enrolled at year-end. – Achieved tentative FDA authorization for CIP-TRAMADOL ER; subsequent to year end, received favourable summary judgment motion relating to patent litigation.